When does GenSight report earnings and why does it matter for SIGHT.PA stock?

GenSight reports on **20 Mar 2026**. The earnings release often includes clinical updates and cash position details, which are primary drivers for SIGHT.PA stock because the company is pre-commercial and valuation depends on trial milestones.

What is Meyka AI's short-term forecast for SIGHT.PA stock?

Meyka AI's forecast model projects a monthly price of **€0.07**, implying about **-16.47%** versus the current **€0.0838**. Forecasts are model-based projections and not guarantees.

What are the main risks that could push SIGHT.PA stock lower?

Major risks include negative clinical outcomes, further cash shortfalls, and dilution from financing. Low liquidity and a current ratio of **0.11** increase downside sensitivity for SIGHT.PA stock.

Are there specific price targets to use for trading SIGHT.PA stock?

Scenario targets: Bear **€0.04** (down **-52.28%**), Base **€0.09** (up **7.40%**), Bull **€0.20** (up **138.76%**). Use targets with tight risk controls due to high volatility.

EU Stocks

SIGHT.PA stock: GenSight Biologics €0.0838 after-hours, earnings 20 Mar 2026

ByHuzaifa Zahoor March 20, 2026March 20, 2026

SIGHT.PA stock opened after-hours at €0.0838, down 1.30% as investors digest GenSight Biologics S.A. results due 20 Mar 2026. The clinical-stage biotech reports on earnings today amid thin liquidity and heavy year-to-date declines. We focus on the numbers that move price: cash runway, EPS of -0.13, and trial milestones for LUMEVOQ and GS030.